Product Code Database
Example Keywords: mobile phones -raincoat $20
   » » Wiki: Eth-lad
Tag Wiki 'Eth-lad'.
Tag

ETH-LAD, or ETHLAD, also known as 6-ethyl-6-nor-LSD, is a of the lysergamide family related to lysergic acid diethylamide (LSD; also known as METH-LAD).

(2025). 9780123983350, Elsevier.
(1991). 9780849344633, CRC Press. .
It is slightly more potent than LSD and is among the most potent psychedelics known.
(2025). 9783662558782 .
The drug is taken orally.

It acts as a serotonin receptor agonist, including of the 5-HT2A receptor. In addition, it binds to dopamine receptors. The drug produces psychedelic-like effects in animals. It is closely structurally related to LSD and to other psychedelic lysergamides like and .

ETH-LAD was first described in the scientific literature by 1976. Its effects in humans were assessed and reported by Alexander Shulgin in the 1980s and 1990s. The drug was encountered as a novel recreational in by 2016. In addition, a of ETH-LAD, 1P-ETH-LAD, has been developed and encountered as a designer drug.


Use and effects
According to Alexander Shulgin in his book ( Tryptamines I Have Known and Loved), ETH-LAD has a dose of 40 to 150μg orally and a duration of 8 to 12hours. However, it also produced clear effects at a dose of 20μg, and in other publications, Shulgin gave a lower dose range for the drug of 40 to 80μg.
(2025). 9780124339514, Elsevier Science. .
Its onset ranges from 15minutes to 1hour and peak effects occur after about 1 to 2hours.

Shulgin has stated that ETH-LAD is "a little more potent" than LSD or roughly twice as potent as LSD in humans. Other researchers have described it as "slightly more potent" or "somewhat more potent" than LSD in humans. For comparison, Shulgin lists the dose range of LSD as 60 to 200μg or 50 to 200μg in his publications. Based on the preceding findings, ETH-LAD is one of the most potent serotonergic psychedelics known in humans, if not the most potent known psychedelic. As a result of this, it has been said that LSD can no longer be considered the most potent psychedelic.

The effects of ETH-LAD have been reported to include closed-eye imagery, very few visual changes or distortions, gentle movements of objects, LSD-like visual aspects, two-dimensional surfaces looking three-dimensional, objects looking "magical", and possible . It was described as making the body feel balanced, thinking being easy, concepts easy to follow through, mind capable of realistic and down-to-earth thought, and warmth and humor being present. Other reported effects included feeling , effects, no , effects, stomach discomfort, and .

Compared to LSD, ETH-LAD was described as lacking the push and sparkle of LSD, allowing for extraordinary experiences with none of LSD's demands, being less aggressive than LSD and lacking its "taking control" nature, having a greatly modified degree of visual distortion relative to LSD, having visual effects similar to LSD but much more gentle, and being more allowing than demanding.


Interactions

Pharmacology

Pharmacodynamics
ETH-LAD acts as a serotonin receptor agonist, including of the 5-HT2A receptor. Alt URL It shows greater potency and as a serotonin 5-HT2A receptor agonist than LSD . In addition to the serotonin 5-HT2A receptor, the drug binds with high affinity to the serotonin 5-HT1A and 5-HT2C receptors. Like LSD, ETH-LAD also binds with lower affinity to the D1, D2, D3, D4, and D5 receptors.

ETH-LAD shows psychedelic-like effects in animals, specifically rodent drug discrimination tests. It is about 1.6- to 2.3-fold more potent than LSD in these tests. Similarly to LSD, ETH-LAD shows moderate anti-inflammatory effects in preclinical research, but with slightly higher potency.


Pharmacokinetics
The of ETH-LAD has been studied.


Chemistry
ETH-LAD, also known as 9,10-didehydro- N, N,6-triethylergoline-8β-carboxamide or as 6-ethyl-6-nor-LSD, is a substituted lysergamide derivative related to lysergic acid diethylamide (LSD; also known as METH-LAD). It is the 6- derivative of (6-nor-LSD; H-LAD) and is the derivative of LSD with an ethyl group instead of at the 6 position of the ring system.


Properties
According to Alexander Shulgin, ETH-LAD may be chemically unstable in solution.


Synthesis
The chemical synthesis of ETH-LAD has been described.


Analogues
Analogues of ETH-LAD include , , , , , , and , among others. 1P-ETH-LAD, a of ETH-LAD, has been developed and encountered as a novel .


History
ETH-LAD was first described in the scientific literature by Tetsukichi Niwaguchi and colleagues by 1976. Subsequently, its preclinical was studied and described by Andrew J. Hoffman and David E. Nichols in 1985. ETH-LAD's properties and effects in humans were assessed by Alexander Shulgin. These observations were reported via personal communication by Nichols in 1986, later described by Shulgin himself in a 1994 literature review, and described in-depth by Shulgin himself in his 1997 book ( Tryptamines I Have Known and Loved). ETH-LAD was encountered as a novel in by 2016.


Society and culture

Legal status

Switzerland
ETH-LAD is illegal in as of December 2015.


United Kingdom
On June 10, 2014, the Advisory Council on the Misuse of Drugs (ACMD) recommended that ETH-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use. The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015.


See also


External links

Page 1 of 1
1
Page 1 of 1
1

Account

Social:
Pages:  ..   .. 
Items:  .. 

Navigation

General: Atom Feed Atom Feed  .. 
Help:  ..   .. 
Category:  ..   .. 
Media:  ..   .. 
Posts:  ..   ..   .. 

Statistics

Page:  .. 
Summary:  .. 
1 Tags
10/10 Page Rank
5 Page Refs
1s Time